Jade Biosciences (JBIO) Total Liabilities (2020 - 2026)

Jade Biosciences has reported Total Liabilities for 7 years, with the latest figure at $23.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 823.64% year-over-year to $23.0 million; the trailing twelve-month figure through Mar 2026 stood at $23.0 million (up 823.64% YoY), and the FY2025 full-year result was $17.3 million, down 85.57% from the prior year.
• Total Liabilities for Q1 2026 stood at $23.0 million, up from $17.3 million in the prior quarter.
• The five-year high for Total Liabilities was $119.6 million in Q4 2024, with the low at $2.5 million in Q1 2025.
• Historically, Total Liabilities has averaged $19.8 million across 5 years, with a median of $15.2 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities sank 94.49% — and 2026, when it jumped 823.64%.
• Jade Biosciences' Total Liabilities stood at $8.6 million in 2022, then soared by 109.89% to $18.0 million in 2023, then soared by 565.83% to $119.6 million in 2024, then plunged by 85.57% to $17.3 million in 2025, then surged by 33.06% to $23.0 million in 2026.
• The last three Total Liabilities figures came in at $23.0 million (Q1 2026), $17.3 million (Q4 2025), and $23.1 million (Q3 2025), per Business Quant data.